Key Points
- Insider selling: VP Jeffrey Zerillo sold 281 shares on Dec. 1 at $60 (and previously sold 719 shares on Nov. 28), totaling 1,000 shares for $60,000, trimming his stake by 0.66% to 42,048 shares (≈$2.52M).
- Company performance and market view: Prestige beat last quarter's EPS ($1.07 vs. $0.97) with $274.1M revenue (down 3.4% YoY), the stock trades near its 52‑week low (52‑week range $57.25–$90.04), and analysts assign a consensus target of $85.33 with a "Moderate Buy" average rating.
Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) VP Jeffrey Zerillo sold 281 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $60.00, for a total transaction of $16,860.00. Following the sale, the vice president owned 42,048 shares of the company's stock, valued at approximately $2,522,880. This represents a 0.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Jeffrey Zerillo also recently made the following trade(s):
- On Friday, November 28th, Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock. The shares were sold at an average price of $60.00, for a total transaction of $43,140.00.
Prestige Consumer Healthcare Price Performance
Shares of PBH stock opened at $59.80 on Wednesday. Prestige Consumer Healthcare Inc. has a 52-week low of $57.25 and a 52-week high of $90.04. The stock has a market cap of $2.88 billion, a PE ratio of 14.04, a PEG ratio of 1.93 and a beta of 0.39. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The firm's 50 day moving average price is $61.16 and its two-hundred day moving average price is $70.21.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The company had revenue of $274.11 million for the quarter, compared to the consensus estimate of $257.14 million. During the same quarter in the prior year, the business posted $1.09 EPS. The firm's quarterly revenue was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. As a group, analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP lifted its position in Prestige Consumer Healthcare by 4.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company's stock valued at $161,723,000 after acquiring an additional 119,459 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Prestige Consumer Healthcare by 4.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company's stock valued at $100,893,000 after purchasing an additional 70,376 shares during the period. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in shares of Prestige Consumer Healthcare by 45.3% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company's stock valued at $135,903,000 after purchasing an additional 493,199 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Prestige Consumer Healthcare by 0.7% during the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company's stock worth $112,843,000 after buying an additional 9,455 shares during the period. Finally, Invesco Ltd. grew its holdings in shares of Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock worth $113,635,000 after buying an additional 261,537 shares in the last quarter. Institutional investors own 99.95% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on the company. Jefferies Financial Group decreased their target price on Prestige Consumer Healthcare from $75.00 to $71.00 and set a "hold" rating for the company in a research report on Monday, October 27th. Canaccord Genuity Group reduced their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a "buy" rating on the stock in a research note on Friday, November 7th. Oppenheimer decreased their price objective on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an "outperform" rating for the company in a report on Tuesday, October 21st. Wall Street Zen lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Moderate Buy" and a consensus target price of $85.33.
Read Our Latest Stock Analysis on Prestige Consumer Healthcare
Prestige Consumer Healthcare Company Profile
(
Get Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
